RNA sequencing analysis reveals apoptosis induction by hydrogen treatment in endometrial cancer via TNF and NF-κB pathways
Yang Y, Liu YP, Bao W, Chen JS, Xi XW. · Translational cancer research. 2020;9(5):3468-3482.
What kind of evidence is this?
Preclinical
Controlled cell or tissue study
Cancer research
H₂-rich water
Not reported in this record.
Not reported in this record.
Methods at a glance
cell, cells used to study cancer research.
Preclinical study; the article does not state one consolidated sample total, so no total is inferred.
Multiple article-specific time points; see the linked full methods.
Full text reports H₂ dissolved in drinking water. Detected intervention quantities or schedules: 28 mL, 0.7 ppm, 8 mL, 4 mL, 5%, 0.6 mmol/L.
H₂ dissolved in drinking water — H₂ only unless the full text explicitly reports oxygen co-delivery.
H₂-related quantities reported in the intervention passages: 28 mL, 0.7 ppm, 8 mL, 4 mL, 5%, 0.6 mmol/L. Values are not combined across different experimental arms.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “As we put emphasis on aspect of inflammatory and cell death in hydrogen treated endometrial cancer cells, GO pathway enrichment analysis demonstrated that the…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. Funding or grant information is reported in the full article. The article declares no conflicts of interest.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 35117712 · DOI: 10.21037/tcr.2020.03.71
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10